Auris Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>AM</div>
EARS -- USA Stock  

USD 1.15  0.11  10.58%

My story will sum up Auris Medical. We will evaluate why recent Auris Medical price moves suggest a bounce in December. Auris Medical Holding is currently traded for 0.81. The entity has historical hype elasticity of 0.01. The average price elasticity to hype of competition is about 0.14. The firm is forecasted to increase in value after the next press release, with the price going to jump to 0.82. The latest volatility of headline impact on the company stock price is is way over 100 percent making price predictions on social media along less reliable. The price gain on the next news is estimated to be 1.23%, whereas the daily expected return is currently at -0.32%. Given the investment horizon of 30 days, the next forecasted announcement will be in about 4 days.
Published over a week ago
View all stories for Auris Medical | View All Stories
Will Auris Medical (NASDAQ:EARS) price continue slumping?
This firm's average rating is Buy from 3 analysts. We provide trade advice to complement the prevailing expert consensus on Auris Medical Holding. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
The successful prediction of Auris Medical stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Auris Medical Holding, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Auris Medical based on Auris Medical hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Auris Medical's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Auris Medical's related companies.

Watch out for price decline

Please consider monitoring Auris Medical on a daily bases if you are holding a position in it. Auris Medical is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Auris Medical stock to be traded above the $1 level to remain listed. If Auris Medical stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

Use Technical Analysis to project Auris expected Price

Auris Medical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Auris Medical technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Auris Medical trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Auris utilizes its cash?

To perform a cash flow analysis of Auris Medical, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Auris Medical is receiving and how much cash it distributes out in a given period. The Auris Medical cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Auris Medical Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Auris Medical reported last year Net Cash Flow from Operations of (8.39 Million)

Another Deeper Perspective

The latest fall in stock price could raise concerns from retail investors as the firm it trading at a share price of 0.81 on very low momentum in volume. The company executives have failed to build on market volatilities in October. However, diversifying your overall positions with Auris Medical Holding may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 30 days investing horizon is currently 5.33. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Auris Medical partners.
 2017 2018 2019 2020 (projected)
Current Assets15.87 M6.06 M2.37 M2.44 M
Total Assets17.83 M9.88 M9.23 M9.47 M

Tax Assets Breakdown

Auris Medical Tax Assets yearly trend continues to be relatively stable with very little volatility. Tax Assets are likely to drop to about 29.3 K. Tax Assets usually refers to a component of Total Assets representing tax assets and receivables. Auris Medical Tax Assets are relatively stable at the moment as compared to the past year. Auris Medical reported last year Tax Assets of 29,484.9
2010
2019
2020
201032,761
201929,484.9
202029,312.47

How will Auris retail investors react to the next fall?

Latest mean deviation is at 3.3. Auris Medical Holding exhibits very low volatility with skewness of 1.77 and kurtosis of 8.01. However, we advise investors to further study Auris Medical Holding technical indicators to make sure all market info is available and is reliable. Auris Medical Holding is a potential penny stock. Although Auris Medical may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Auris Medical Holding. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

The Current Takeaway on Auris Medical Investment

While some other companies in the biotechnology industry are either recovering or due for a correction, Auris Medical may not be performing as strong as the other in terms of long-term growth potentials. The inconsistency in the assessment between current Auris valuation and our trade advice on Auris Medical is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Auris Medical.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Auris Medical Holding. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com